| Study |
Reference |
|
Botton, 2025
|
Botton Exposition paternelle au valproate au cours de la spermatogenèse et risque de troubles neuro-développementaux chez l’enfant : étude nationale à partir du registre EPI-MERES. GIS EPI- PHARE-ANSM-CNAM – Rapport EPI-PHARE. Saint-Denis, 6 novembre 2025, 61 pages.
|
|
Christensen (Controls exposed to LTG/LEV), 2024
|
Christensen Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open 2024; 7:e2414709 Christensen Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During Spermatogenesis. JAMA Netw Open 2025; 8:e2512139
|
|
Christensen (Controls unexposed, general pop), 2024
|
Christensen Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open 2024; 7:e2414709 Christensen, J. Paternal use of valproate during spermatogenesis and risk of offspring congenital malformations and neurodevelopmental disorders - A Danish cohort study Epilepsia 2024; 65:24-.
|
|
Christensen (Controls unexposed, sibling), 2024
|
Christensen Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open 2024; 7:e2414709
|
|
Christensen (Controls unexposed, sick), 2024
|
Christensen Valproate Use During Spermatogenesis and Risk to Offspring. JAMA Netw Open 2024; 7:e2414709
|
|
Colas_Norway, 2025
|
Colas Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring. JAMA Netw Open 2025; 8:e2542581 Colas, S. Paternal Exposure to Valproate and The Risk of Neuro-Developmental Disorders in Offspring: A Population-Based Cohort Study in Denmark, Norway and Sweden Pharmacoepidemiol. Drug Saf. 2024; 33:1-. IQVIA A post-authorisation safety study to evaluate the paternal exposure to valproate and the risk of neurodevelopmental disorders including autism spectrum disorder as well as congenital abnormalities in offspring - a population-based retrospective study PASS Study report 2023 V1.1
|
|
Meng_Norway (Controls exposed to LTG/LEV), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Meng_Norway (Controls unexposed, general pop), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Meng_Norway (Controls unexposed, sick), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Meng_Taiwan (Controls exposed to LTG/LEV), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Meng_Taiwan (Controls unexposed, general pop), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Meng_Taiwan (Controls unexposed, sick), 2026
|
Meng Paternal exposure to valproate and risk of neurodevelopment disorders in children - A nationwide registry-based in Norway Pharmacoepidemiology and Drug Safety, 2025; 34(S1):42 Meng Valproate Use by Fathers and Risk of Neurodevelopmental Disorders in Children. NEJM Evid 2026; 5:EVIDoa2500254 Meng Valproate Use by Fathers During Spermatogenesis and Risk of Neurodevelopmental Disorders in Children: A Cross-National Study from Norway and Taiwan Drug Saf. 2025; 48:1456-.
|
|
Razaz_Norway, 2026
|
Razaz Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis. J Neurol Neurosurg Psychiatry 2026; :
|
|
Razaz_Sweden, 2026
|
Razaz Risk of neurodevelopmental disorders associated with paternal use of valproate during spermatogenesis. J Neurol Neurosurg Psychiatry 2026; :
|
|
Tomson, 2020
|
Razaz, N. Paternal exposure to antiepileptic drugs and offspring outcomes: Nationwide Population-based Cohort Study in Sweden Paediatr. Perinat. Epidemiol. 2021; 35:74-. Tomson Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden. J Neurol Neurosurg Psychiatry 2020; 91:907-913
|
